129 results about "Urokinase" patented technology

The invention provides a separation and purification method of urokinase, and relates to the technical field of separation and extraction. The separation and purification method comprises the following steps: S1, regulating the pH value of male urine to 8.5, standing, and taking supernate; s2, mixing the supernate with an adsorption material, and eluting with an eluent to obtain a urokinase crude product solution; the adsorption material is a core-shell silica gel polymer, Fe3O4atSiO2-NH2 is taken as a core, and polystyrene is taken as a shell; the eluent is a sodium citrate buffer solution with the concentration of 0.5 to 0.15 M, acetonitrile with the concentration of 1 to 5 weight percent and EDTA (Ethylene Diamine Tetraacetic Acid) with the concentration of 0.5 to 1.5 mM; and S3, carrying out anion exchange column chromatography on the urokinase crude product solution, eluting with an eluent, and precipitating to obtain the urokinase. The urokinase prepared by the method has the advantages of high polymer urokinase content, high recovery rate and high activity yield.

The invention discloses an ultramicro nano thrombolytic microbubble as well as a preparation method and application thereof, and belongs to the technical field of drug-loaded microbubbles. The thrombolytic microbubble comprises a core drug and a lipid shell, wherein the core drug comprises an anti-active oxygen material, urokinase and perfluoropentane; the preparation method comprises the following steps: firstly preparing the anti-active oxygen material, then encapsulating the anti-active oxygen material with liposome, adding urokinase for hydration after encapsulation, adding perfluoropentane, emulsifying, and freeze-drying to obtain the thrombolytic microbubble. The ultramicro nano thrombolysis microbubble is used for treating thrombus, phase change occurs to perfluoropentane under the ultrasonic action, so that thrombus is developed more obviously under the ultrasonic action, meanwhile, urokinase and an anti-active oxygen material are released from the microbubble through the cavitation effect, the released urokinase can deepen into the thrombus under the blasting action of the perfluoropentane, and the thrombolysis effect of the thrombus is improved. And the anti-active oxygen material can remove active oxygen and protect vascular endothelial cells and macrophages after revascularization, so that the risk of bleeding is reduced.

The present invention includes a method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse, comprising: determining a level of expression for two or more biomarkers selected from urokinase plasminogen activator (uPA), kallikrein-8 (hK8), kallikrein-11 (hK11), or desmoglein-3 (DSG3) in a biological sample of a subject when compared to the same type of sample from a subject or a population of subjects that do not have RRMS; diagnosing that the subject in undergoing relapse if the level of expression of the two or more biomarkers has decreased in the subject; and administering a therapeutically effective amount of treatment for RRMS to the subject.

A compound for preventing and treating cancer has a first binding peptide from a urokinase-type plasminogen receptor (uPAR) antagonist, the first binding peptide being operably linked to an antibody peptide, the antibody peptide being operably linked to a second binding peptide from an endostatin or plasminogen-derived peptide sequence.

Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.

This invention belongs to the field of urea preparation technology and discloses a large-particle urea, composed of the following raw materials in a specific ratio: a 50% concentration of dilute urine solvent, a urokinase activity inhibitor, and a pigment, in a ratio of 100:6:5. This solution, through the careful design of the 50% concentration of dilute urine solvent, the urokinase activity inhibitor, and the pigment, enhances the soil dissolution rate and utilization rate. The addition of the urokinase activity inhibitor effectively inhibits the rapid hydrolysis of urea, reduces ammonia nitrogen loss, improves nitrogen utilization, mitigates negative environmental impacts, and contributes to soil ecological balance. The use of large-particle morphology and strict moisture control technology ensures the product's moisture resistance and storage stability, extending its shelf life. During production, the temperature is precisely controlled at 30℃, which avoids urine crystallization, ensures the full dissolution of the urokinase activity inhibitor, avoids odors generated at high temperatures, reduces environmental pollution, and improves the product's environmental friendliness.

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.

A thrombus suction negative pressure suction device comprises an injection needle tube, a piston is arranged in the injection needle tube in a sliding mode, the head end of the injection needle tube is connected with a connecting sleeve, the head end of the injection needle tube is connected with symmetrically-distributed air outlet tubes, a limiting frame is arranged in each air outlet tube, an air blocking plate is arranged on each limiting frame in a sliding mode, and the air blocking plates are connected with the connecting sleeves in a sliding mode. The air blocking plate is used for sealing the air outlet pipe, the air blocking plate is sleeved with a first elastic piece, and a first ball valve is arranged in the connecting sleeve. By arranging the liquid storage tube on the injection needle tube, a urokinase solution can be directly injected into the suction catheter without additionally using a three-way valve, the overall operation is simpler, and the injection needle tube and the suction catheter can be blocked through the first ball valve, so that the injection needle tube and the suction catheter can be independently operated; and the injection needle tube can exhaust internal air through the air blocking plate, negative pressure is achieved, air is prevented from entering the suction catheter, and therefore it is guaranteed that the suction catheter is in a stable negative pressure state.

The present invention discloses a Lactobacillus crispatus strain for improving thrombosis and vascular health and its products and applications, and relates to the technical field of microorganisms. The present invention discloses a Lactobacillus crispatus strain, which is Lactobacillus crispatus ( Lactobacillus crispatus ) NHNK‑608, which was deposited in the China Center for Type Culture Collection on March 7, 2024, and its deposit number is CCTCC NO: M 2024421. Experiments have shown that NHNK‑608 has the functions of dissolving blood clots, promoting the production of urokinase, increasing the anticoagulant factor of vascular endothelial cells, promoting the growth of vascular endothelial cells, promoting the repair of oxidative damage of vascular endothelial cells, and reducing inflammation and apoptosis of vascular endothelial cells. The bacterial biofilm increases the colonization ability of mucin and intestinal epithelial cells, and can be used to prepare products that improve blood clots and vascular health.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The utility model relates to the field of urokinase extraction, and discloses a urine and water diverter for separating and extracting urokinase from human urine, which comprises a shell, a protective cover is arranged at the top end of the shell, a filter plate is arranged on the inner wall of the shell, a driving motor is fixedly connected to the top end of the protective cover, and an output shaft of the driving motor penetrates through and rotates on the inner wall of the protective cover. A cleaning assembly is arranged at the bottom end of an output shaft of the driving motor and comprises a connecting rod, the top end of the connecting rod is fixedly connected to the bottom end of the output shaft of the driving motor, and stirring blades are fixedly connected to the outer side of the connecting rod. According to the urine separating and filtering device, the driving motor, the cleaning assembly and the filtering plate are used in cooperation, when urine is separated and filtered, the cleaning brush can be driven by the driving motor to clean the filtering net, it is ensured that the filtering efficiency is continuous and stable, then the urine is stirred through the stirring blades, and therefore dispersion of impurities in the urine is promoted; and the risk of blockage of the filter screen is reduced.

Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some cases, the antibodies are cross-reactive with one or more non-human animal uPAR polypeptides, such as non-human primate uPAR, e.g., cynomolgus monkey uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins, and conjugates of the present disclosure to treat conditions associated with uPAR expression and / or activity are also provided. In some embodiments, the condition associated with uPAR expression and / or activity is cancer. Non-limiting examples of such cancers include cancers characterized by cancer cells expressing uPAR on their surface, cancers characterized by stromal cells within the tumor microenvironment expressing uPAR on their surface, and the like.

Disclosed herein, are peptides that bind urokinase-type plasminogen activator receptors. The peptides may comprise amino acid sequences of IPPWEAPK (SEQ ID NO: 1), DLAQCQTPTQAAPPTPVSPR (SEQ ID NO: 2), or LHVPLMPAQPAPPK (SEQ ID NO: 3), or retro-inverso amino acid sequences of the above enumerated sequences. Also described herein, are methods of administering compounds comprising peptides that bind urokinase-type plasminogen activator receptors to subjects for the treatment of ovarian cancer and improving wound closure.

The invention discloses a PICC (Peripherally Inserted Central Catheter) thrombolysis device which comprises a connector connected with a PICC pipeline; the liquid storage tank is connected with the connector; the negative pressure pipe generates a negative pressure environment in the connector; a first connector, a second connector and a third connector are arranged on the connector, the first connector and the second connector are arranged at the two ends of the connector respectively, a branch pipe is arranged on the connector, the third connector is arranged on the branch pipe, the liquid storage tank is connected to the second connector, and the negative pressure pipe is connected to the third connector; the liquid storage tank is filled with urokinase liquid; a sealing plate is arranged in the connecting cavity and seals the second connector. A first push rod is arranged on the negative pressure pipe, after the first push rod is pressed down, the sealing plate moves to the third connector to seal the third connector, the second connector is opened, and urokinase liquid enters the connector; the method has the advantage of being convenient to operate.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The current invention relates to a polypeptide comprising an immunoglobulin single variable domain and an urokinase-type plasminogen activator (uPA) domain wherein the immunoglobulin single variable domain is able to bind to fibrin via a fibrin-binding domain.

The utility model relates to an automatic urokinase injection device suitable for lower limb artery stenosis, which is characterized in that a urokinase injection controller shell (3-4) is provided with a urokinase injection controller front cover (3-6) through a hinge and a buckle, the inner side of the urokinase injection controller shell (3-4) is provided with an extrusion ring (3-5), the original point of the round urokinase injection controller shell (3-4) is provided with a driving shaft (3-1), and the urokinase injection controller front cover (3-6) is provided with an extrusion ring (3-5). Extrusion roller driving arms (3-2) are installed on the side edge of the driving shaft (3-1) at equal intervals, the tail ends of the extrusion roller driving arms (3-2) are connected with extrusion rollers (3-3) through rotating shafts, and the extrusion rollers (3-3) roll on the surfaces of the extrusion rings (3-5); a stepping motor arranged in the driving main machine (1) drives a driving shaft (3-1), and a battery pack and a controller are arranged in the driving main machine (1). The urokinase injection device can accurately control injection of urokinase, can effectively reduce pressure of medical staff, improves injection speed accuracy, and controls use cost.

The present invention relates to a fluorescent probe based on a lanthanide metal organic framework, a preparation method and an application, and belongs to the field of nanomaterial technology. The fluorescent probe provided by the present invention is obtained by covalently cross-linking a lanthanide metal organic framework with a neutrophil elastin binding peptide and a P-selectin binding peptide, and the surface of the lanthanide metal organic framework is modified with a tetracyclic antibiotic and arginine. The fluorescent probe prepared by the present invention specifically targets activated platelets and neutrophils, does not affect cell survival rate, does not cause hemolysis of red blood cells, and can be applied to the preparation of diagnostic products for thrombotic diseases. The use of a fluorescent probe loaded with urokinase achieves stable and efficient delivery of urokinase, inhibits platelet aggregation, slows down blood clot contraction, has a good thrombolytic effect, and has the potential to be used in the preparation of drugs for the treatment of thrombotic diseases. The materials required for the present invention are easy to obtain, the preparation method is simple, and a new method is provided for the diagnosis and treatment of thrombotic diseases.

The present invention includes a method of treating a subject suffering from recurrent-remitting multiple sclerosis (RRMS) that is experiencing recurrence, comprising: determining that a sample of the same type from a subject or population of subjects that does not suffer from RRMS is less than a sample of the same type from a subject or population of subjects that does not suffer from RRMS; the expression level of two or more biomarkers selected from the group consisting of a urokinase plasminogen activator (uPA), kallikrein 8 (hK8), kallikrein 11 (hK11) or desmoplasmin 3 (DSG3) in a biological sample of the subject, determining the expression level of two or more biomarkers selected from the group consisting of urokinase plasminogen activator (uPA), kallikrein 8 (hK8), kallikrein 11 (hK11) and desmoplasmin 3 (DSG3); if the expression level of the two or more biomarkers in the subject is reduced, diagnosing the subject being experiencing recurrence; and administering to the subject a therapeutically effective amount of a treatment for RRMS.

The disclosure provides urokinase plasminogen activator receptor (uPAR) binding polypeptides (e.g., uPAR antigen binding proteins), and fusion proteins comprising said uPAR binding polypeptides and a cytokine or variant thereof. The disclosure further provides pharmaceutical compositions comprising the uPAR binding polypeptides and fusion proteins of the disclosure and methods of treating cancer with the same. The disclosure further provides engineered IL-12 p35 and p40 polypeptides.

The present invention relates to a positron emitting imaging agent for prognostic use in patients with neuroendocrine tumors (NENs) undergoing PET imaging for cancer, said imaging agent comprising a uPAR binding peptide linked to the radionuclide 68Ga or 64Cu via the chelators NOTA or DOTA. The present invention also relates to a composition comprising a radiopharmaceutical for use in treating or alleviating neuroendocrine tumors (NENs) in a subject, said radiopharmaceutical comprising a radionuclide and a uPAR binding peptide. Figure 4A will be published together with the abstract.

The application discloses an engineered exosome targeting human urokinase-type plasminogen activator receptor uPAR and a preparation method and application thereof. Firstly, a high-affinity anti-human uPAR single-domain antibody VHH is prepared; then, a human umbilical cord mesenchymal stem cell engineering cell line expressing a VHH-PTGFRN fusion protein is constructed, and the engineered exosome is prepared and purified by combining three-dimensional hypoxic culture, chemical induction and size-exclusion chromatography technology. The engineered exosome comprises four comparative samples, wherein the core sample Exo^(VHH / miR) can simultaneously display the anti-uPAR VHH on the membrane surface to realize targeted delivery and enrich miR-193b-3p in the chamber to realize gene silencing, and the synergistic effect of the two can efficiently remove the uPAR high-expression senescent cells and inhibit the senescence-associated secretory phenotype SASP. The engineered exosome has the advantages of standardized preparation process, high yield and high purity, strong targeting, excellent curative effect and good safety, and can be used for preparing a treatment preparation for anti-aging and aging-related diseases, and has important clinical application value.

The invention provides a preparation method of an aprotinin affinity chromatographic column. Specifically, the aprotinin is used as a raw material and is coupled with CNBr activated agarose gel Focurose 4FF to prepare the aprotinin affinity chromatographic column. The coupling reaction in the preparation method is simple and easy to control, the reaction condition is mild, the operation is convenient, the repeatability is high, and industrial amplification is easy. The affinity column prepared by the invention can completely remove human urinary kallidinogenase in urokinase, and can be repeatedly used for multiple times.

The invention discloses preparation and application of macrophage targeting nanoparticles entrapped with a cell burial function accelerant. The medicine for enhancing the intercellular function of the macrophages is a liver X receptor stimulant, and the liver X receptor stimulant comprises at least one of T0901317, GW3965, Ouabagenin and LXR-623. The surface of the targeting nanoparticle is coated with a macrophage cell membrane, and meanwhile, a urokinase type plasminogen activator receptor (uPAR) targeting ligand is modified. The nanoparticle can be efficiently accumulated at an inflammatory focus part by utilizing a macrophage cell membrane, and the modified targeting ligand is used for targeting the macrophage with damaged cell burial function, so that the cell burial function of the macrophage is enhanced, the polarization of the macrophage to an anti-inflammatory phenotype is promoted, the release of anti-inflammatory and proinflammatory cytokines is regulated, and the anti-inflammatory effect of the nanoparticle is improved. And finally, the inflammatory microenvironment of a focus part is regulated and controlled, so that a good effect of treating autoimmune diseases is achieved.

Provided are modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and / or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.

The invention provides a composite microsphere, a preparation method and application thereof, and a urokinase purification method, and belongs to the field of bioengineering and chemical engineering. The composite microsphere is prepared from the following raw materials: modified nano ferroferric oxide, polylactic acid, polylysine and arginine. According to the invention, the composite microspheres comprising modified nano ferroferric oxide, polylactic acid, polylysine and arginine are used as chromatographic column filler, and a urokinase raw material solution is subjected to chromatographic column treatment, so that the adsorption capacity to endotoxin can be effectively improved, and the activity of urokinase is improved.

A product, composition, suspension and / or method to dissolve vaso-occlusive clots in vivo in a sickle diseased subject utilizing Target-specific Thrombolytic Urokinase Spheres (TTUS). The TTUS can target vaso-occlusive clots in vivo and then lyse the obstructive blood clots with high efficiency can be intravenously administered to a subject in need thereof. The TTUS are configured to dissolve vaso-occlusive clots by converting plasminogen in blood of the subject into plasmin molecules that dissolves the clot. The nanospheres can encapsulate an enzymatically active bioreactive agent, such as urokinase. Since the active enzyme is targeting and binding essentially only to obstructive clots, there is minimal risk of side-effects to the subject. The nanospheres are less than one micron in diameter, resulting in a size much smaller than red blood cells.

Novel urokinase-type plasminogen activator receptor (uPAR) binding molecules and soluble urokinase-type plasminogen activator receptor (suPAR) binding molecules and methods of their use are disclosed.

The utility model discloses a urokinase eluent recovery device which comprises a base, a mounting rack is arranged above the base, an elution tank is fixedly arranged on the base, four groups of symmetrically distributed liquid collecting tanks are arranged on the mounting rack, the liquid collecting tanks and the elution tank are correspondingly distributed, a mounting ring is arranged above the elution tank, and the mounting ring is arranged on the mounting rack. A mounting ring is arranged below the elution tank, a scraping rod is fixedly mounted on the mounting ring, the scraping rod is attached to the inner wall of the elution tank, a cleaning block is arranged on the scraping rod, the cleaning block is in sliding connection with the scraping rod, a rotating ring is arranged below the elution tank, a plurality of groups of annularly distributed bottom plates are arranged below the elution tank, and the plurality of groups of bottom plates are rotationally connected with the elution tank through mounting shafts; the multiple sets of annularly-distributed bottom plates are matched with the scraping rods and the cleaning blocks, so that complete cleaning of kieselguhr on the inner wall of the elution tank is achieved, and the situation that the next use of the eluent recovery device is affected due to the fact that residual kieselguhr cannot be completely cleaned is avoided.